Dr. Leon-Ferre is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
200 1st St SW
Rochester, MN 55905Phone+1 507-284-2511
Summary
- Dr. Roberto Leon-Ferre is an oncologist in Rochester, MN and is affiliated with Mayo Clinic Hospital - Rochester. He received his medical degree from Universidad Catolica de Santiago de Guayaquil and has been in practice 10 years. He also speaks multiple languages, including Spanish. He specializes in breast cancer, and immuno oncology.
Education & Training
Mayo Clinic College of Medicine and Science (Rochester)Fellowship, Hematology and Medical Oncology, 2014 - 2017
University of Iowa Hospitals and ClinicsChief Residency, Internal Medicine, 2013 - 2014- University of Iowa Hospitals and ClinicsResidency, Internal Medicine, 2010 - 2013
Universidad Catolica de Santiago de GuayaquilClass of 2007
Certifications & Licensure
MN State Medical License 2014 - 2025
IA State Medical License 2010 - 2015- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Treatment of a Resistant Disease Using Decitabine Combined With Vemurafenib Plus Cobimetinib Start of enrollment: 2013 Oct 01
- Oxybutynin Chloride in Managing Hot Flashes Start of enrollment: 2016 Dec 09
- Impact of Neoadjuvant Chemotherapy on the Peripheral Blood Immune Phenotype in Operable Breast Cancer Start of enrollment: 2021 Jun 09
- Join now to see all
Publications & Presentations
PubMed
- 67 citationsAdvances in systemic therapies for triple negative breast cancer.Roberto A Leon-Ferre, Matthew P Goetz
BMJ. 2023-05-30 - 12 citationsDistinct spatial immune microlandscapes are independently associated with outcomes in triple-negative breast cancer.Jodi M Carter, Saranya Chumsri, Douglas A Hinerfeld, Yaohua Ma, Xue Wang
Nature Communications. 2023-04-18 - 129 citationsThe path to a better biomarker: application of a risk management framework for the implementation of PD-L1 and TILs as immuno-oncology biomarkers in breast cancer clin...Paula I. Gonzalez-Ericsson, Elisabeth Specht Stovgaard, Luz F. Sua, Emily Reisenbichler, Zuzana Kos
The Journal of Pathology. 2020-04-01
Press Mentions
Emerging Data Are Expanding Treatment Options, Extending Survival Across Breast Cancer SubtypesSeptember 10th, 2022- Mayo Clinic Research in the News — 6/14/2021June 14th, 2021
- Clinical Challenge: BRCA-Mutant Triple-Negative Breast CancerJune 8th, 2021
- Join now to see all
Professional Memberships
- Associate
- Member
Other Languages
- Spanish
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
